Novo Nordisk secures second licensing deal after mixed investor response

Novo Nordisk signed a second licensing deal following its long-term strategy presentation.

Published 6sem2 sources✓ ConfirmedImportantupdated 6sem

≈ 18sSpeed

The fact

Investors had reacted coolly to the strategy during a recent meeting.

These deals could strengthen the group’s position in developing new treatments.

2 sources — click a link to read an article on the topic:

Explore this topic

Auto-synthesis from 2 media sources · identified on September 29, 2026